Marc Spaanderman has been appointed Professor of Obstetrics at Radboud University/ Radboud university medical center, with effect from 1 March 2020. Prior to his arrival in Nijmegen, Spaanderman was professor and head of the Department of Obstetrics and Gynaecology at Maastricht University/Maastricht UMC+.
Marc Spaanderman (1966, Waldbauer) completed his Master's degree in Medicine at Utrecht University in 1993. He then specialised in gynaecology and obstetrics at Maastricht University, where he earned his PhD in 2001 for research into changes in cardiovascular and renal function in women before and during pregnancy. In addition to healthy women, he examined many women who had suffered from pre-eclampsia, a common cardiovascular disease during pregnancy.
Spaanderman has worked as a researcher and gynaecologist at Maastricht UMC+, the Maxima Medical Centre and Radboud university medical center. In 2012, he was appointed professor in Maastricht. His research interests include preconception counselling, high-risk pregnancy, maternal physiology, gender-sensitive cardiovascular disease and health and health education. Prevention of cardiovascular disease is the central theme in his research.
At Radboud university medical center, Prof. Spaanderman will dedicate himself to building a care and research expertise network within the scientific theme Vascular damage. That network will focus on women with an increased risk of cardiovascular dysfunction with the aim of improving and maintaining health before, during and after pregnancy. Spaanderman will also remain associated with Maastricht UMC+ as a professor and will explicitly strive for intensive and overarching cooperation between the two centres.
Related news items
Evaluation of an AI system for detection of COVID-19 on Chest X-Ray images22 May 2020
In the journal Radiology RIHS researcher Keelin Murphy described how an artificial intelligence system (CAD4COVID-XRay) can identify characteristics of COVID-19 on chest x-rays with performance comparable to six independent radiologists.read more
First clinical trial with genetically modified malaria vaccine completed22 May 2020
In an innovative study, Radboudumc and LUMC jointly tested a candidate vaccine based on a genetically weakened malaria parasite. The results of this clinical trial, published in Science Translational Medicine, show that the vaccine is safe and elicits a defense response against a malaria infection.read more
New step in the development of a vaccine against malaria22 May 2020
A new vaccine based on rodent malaria parasites achieved a 95% reduction in infection of the liver in humans. An international consortium publishes the results in Science Translational Medicine.read more
Retirement of RIMLS Laboratory Assistant Nelly Mulders-Langen19 May 2020
After more than 45 years, Nelly said goodbye to "her" Radboudumc. We are going to miss her dedication and collegiality, but we wish her al the best for the future in good health.read more